Forbion European Acquisition Corp.
FRBN
NASDAQ Global Market21.13
USD
-0.36
- -
CIK
0001874495
CUSIP
G3619H102
Return %
Stock
S&P500
1Y
106.55
26.53
3Y
114.30
76.60
5Y
114.30
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jasper M. Bos
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 4001 Kennett Pike Wilmington DE United States of America 19807
- IPO Date
- Feb 1, 2022
- CIK
- 0001874495
- Website
- forbion.com
- Similar Companies
- Business
- Forbion European Acquisition Corp. (FRBN) is a special purpose acquisition company sponsored by Forbion, a life sciences venture fund manager, focused on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, primarily targeting opportunities in the life sciences industry across Europe. Incorporated in 2021 and headquartered in Wilmington, Delaware, with sponsor operations based in Naarden, the Netherlands, and additional offices in Munich, Germany, and Singapore, the company conducts no significant independent operations but leverages Forbion's expertise in sourcing and executing deals within biotechnology, genetic medicines, and related sectors serving clinical-stage developers and institutional investors. In October 2023, Forbion European Acquisition Corp. completed a reverse merger with enGene, Inc., a clinical-stage genetic medicines company developing non-viral gene therapies via its proprietary Dually Derivatized Oligochitosan (DDX) platform for mucosal tissue applications including non-muscle invasive bladder cancer treatments like EG-70 (detalimogene voraplasmid) in Phase 2 studies; the transaction included $138 million in gross proceeds from PIPE financing anchored by Forbion Growth and investors such as BVF Partners, Omega Funds, and Vivo Capital, enabling enGene's public listing under ticker ENGN on Nasdaq.
enGene (Nasdaq: ENGN) Launched as Publicly Traded Genetic Medicines Company
Why Is Forbion European Acquisition (FRBN) Stock Up 100% Today?